Health Care & Life Sciences » Biotechnology | Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
57.21 M
Public Float
53.66 M
Corbus Pharmaceuticals Holdings Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.19
Market Cap
$440.87 M
Shares Outstanding
64.46 M
Public Float
59.12 M

Profile

Address
500 River Ridge Drive
Norwood Massachusetts 02062
United States
Employees -
Website http://www.corbuspharma.com
Updated 07/08/2019
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Financials

View All
Created with Highcharts 5.0.14Corbus Pharmaceuticals Holdings Inc.Net Income. Fiscal year is January-December. All values USD Thousands.2 5402 5408 8508 85019 99819 99832 42132 42155 67255 67220142015201620172018010k20k30k40k50k60k
Created with Highcharts 5.0.14Corbus Pharmaceuticals Holdings Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.006486481 9111 9112 4402 4404 8224 8222014201520162017201801k2k3k4k5k6k

Yuval Cohen
Chief Executive Officer & Director
John Kenneth Jenkins
Director